Georgitis W J, Merenich J A
Endocrine Service, Fitzsimons Army Medical Center, Aurora, Colorado 80045, USA.
Diabetes Care. 1995 Mar;18(3):345-52. doi: 10.2337/diacare.18.3.345.
To test the effectiveness of pentoxifylline as a therapy for diabetic impotence.
A 3-month placebo-controlled double-blind treatment study was conducted at a single center. Therapeutic response was assessed subjectively by serial self-appraisals of erectile function and objectively by nocturnal penile tumescence (NPT) monitoring.
This cohort of impotent diabetic men displayed substantial neurological and penile vascular dysfunction. Age, body mass index, duration of diabetes, duration of impotence, glycemic control, mode of therapy for non-insulin-dependent diabetes, mean testosterone, mean prolactin, and penile brachial indexes were similar in the treatment (n = 34) and placebo groups (n = 26). NPT monitoring revealed infrequent erectile events, diminished average rigidity, and decreased tumescence. Pentoxifylline did not alter overall glycemic control and did not improve neurological, vascular, or erectile function. In fact, a slight decrease in average percent rigidity from 22 +/- 3 to 17 +/- 2% (mean +/- SE, P < 0.05) was observed in the pentoxifylline-treated group. Although eight (24%) pentoxifylline-treated and five (19%) placebo-treated men reported benefit, no objective improvement was observed in nocturnal tumescence.
Pentoxifylline is not an effective treatment for diabetic erectile dysfunction.
测试己酮可可碱治疗糖尿病性阳痿的有效性。
在单一中心进行了一项为期3个月的安慰剂对照双盲治疗研究。通过对勃起功能的系列自我评估主观评估治疗反应，并通过夜间阴茎勃起（NPT）监测客观评估。
该组糖尿病性阳痿男性表现出明显的神经和阴茎血管功能障碍。治疗组（n = 34）和安慰剂组（n = 26）在年龄、体重指数、糖尿病病程、阳痿病程、血糖控制、非胰岛素依赖型糖尿病治疗方式、平均睾酮、平均催乳素和阴茎肱动脉指数方面相似。NPT监测显示勃起事件少见、平均硬度降低和肿胀减少。己酮可可碱未改变总体血糖控制，也未改善神经、血管或勃起功能。事实上，己酮可可碱治疗组的平均硬度百分比从22±3%轻微降至17±2%（均值±标准误，P<0.05）。虽然8名（24%）接受己酮可可碱治疗的男性和5名（19%）接受安慰剂治疗的男性报告有改善，但夜间肿胀未见客观改善。
己酮可可碱不是治疗糖尿病性勃起功能障碍的有效药物。
